Latest news
Loading news…
Coultreon Biopharma
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 High growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Heverlee, Vlaams-Brabant, Belgium Founded 2025 11-50 employees For Profit
CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
14
2 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 8
- Patents granted
- 14
- Trademarks
- 2
- Top patent class
- Organic Chemistry
- IT spend
- $8.82M
Company Info
- Founded
- 2025
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 21
- HQ
- Heverlee, Vlaams-Brabant, Belgium
- Region
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Signals & Scores
- Heat score
- High
- Growth score
- High
- Trend (7d)
- -0.3
- Trend (30d)
- -4.3
- Trend (90d)
- 9.7
- Last leadership hire
- Jan 8, 2026
Key People at Coultreon Biopharma
Chief Executive Officer
Chief Legal Officer
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Coultreon Biopharma
Loading news…
FAQs about Coultreon Biopharma
People who checked this page also checked these
Browse the full Acquirezy directory.